HopeStage
Back to all studies
UnknownNCT05243329

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant PTSD

Medication studyAges 18–70Canada
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 70 years.

Listed locations
WindsorSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 3, 2022
Recruitment status
Unknown
Enrollment listed in the registry
20
Sponsor
Halucenex Life Sciences Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
From 18 Years to 70 Years
Official registry ID
NCT05243329
Official title
Show the full official title

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Recruitment & locations

Status unknown

Windsor

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Halucenex Life Sciences Inc.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin.

Who can participate?

Listed age limits: 18 years to 70 years.

Want to explore more studies?

Explore studies